Technological Advances in Digital Healthcare, Coronavirus Research, and Global Life Sciences Industries - ResearchAndMarkets.com

DUBLIN--()--The "Technological Advances in Digital Healthcare, Coronavirus Research, and Global Life Sciences Industries" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across digital drug discovery, cancer, synthetic biology, ischemic dieases, diabetes and microbiome therapies. The TOE also provides an analysis of latest advances in novel biologics, drug delivery, small molecules, and coronavirus research.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Innovations in Life Sciences, Health & Wellness

  1. AI Driven Digital Review Platform for Oncology
  2. Computer Aided Drug Design Platform
  3. Drug Discovery Tool for Nonalcoholic Steatohepatitis
  4. Expert Imaging and Machine Learning in Preclinical Trials
  5. Deep Learning Energizing High Multiplex Image Analysis
  6. Enabling the Next Wave of Synthetic Biology
  7. Leveraging Sequencing Technology for High Throughput Results
  8. Repurposing of Remdesivir for the Treatment of Coronavirus
  9. Utilization of Fluorescence for Tumor Detection
  10. Portable, Patient Friendly Dialysis Equipment
  11. Novel Drug For The Treatment of Gastrointestinal Stromal Tumors on Course for FDA Approval
  12. Biologics License Application Filed for New CAR-T Therapy
  13. Promising Drug Combo for Treatment of Diabetes
  14. Novel Treatment Approach for Pancreatic Cancer
  15. Personalized Autologous Cell Therapy for Critical Ischemic Diseases
  16. Best-in-class Bromodomain Inhibitors for the Treatment of Cancer and Other Disorders
  17. Next-generation Nucleic Acid-based Therapies Using Novel Fusogenix Drug Delivery System
  18. Myristoylation-targeted Therapeutics for Hematological and Lung Cancers
  19. Next-generation Protein Engineering Platform
  20. A Probiotic-based Gene Delivery Platform
  21. Converging High-throughput Microfluidics, Machine Vision, and Artificial Intelligence for Novel Antibodies
  22. Precision Pulse Capsulotomy
  23. Computationally-designed De Novo Protein Therapeutics
  24. Promising Phase 2 Results of BTK Inhibitor Drug
  25. Antibody Discovery Project against New Coronavirus Strain
  26. Microbiome Therapy for Graft vs Host Disease

For more information about this report visit https://www.researchandmarkets.com/r/1t6mwe

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900